Katherine Freitas

Immunologist with 10 years of academic research experience and four years of industry experience. Broad expertise in cancer immunotherapy, autoimmune, and CRISPR/Cas9 technologies. Innovative thinking demonstrated by discovery of new pathways that inform the design of next-generation immunotherapies. Proven record of excellence in research evidenced by 11 publications in top-tier journals, presentations at national scientific conferences, and acquisition of competitive research fellowships. Publications include 5 first-author papers (Science 2022, Clinical Immunology 2019), 6 co-author papers (Cancer Cell 2022, Blood Cancer Discovery 2021, Science 2015), and 4 patent applications. Research Skills: -Immunoassays: Isolation and culture of immune cells. Cytotoxicity, Cytokine, and Proliferation assays. -Genetic Engineering: CRISPR/Cas9 and Base Editing. Retroviral and lentiviral vectors. -Flow cytometry and FACS: Cell sorting, high dimensional flow cytometry panel design and analysis. -Bioinformatics: Analysis of single-cell RNA-seq, bulk RNA-seq, and NGS data from pooled screens. -Libraries: CRISPR screens, PCR mutagenesis, yeast display. -Molecular biology: Western blot, molecular cloning, qPCR. -Mouse models: Expertise with xenograft models, humanized mouse models, immune rejection models